Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Parkinson disease (PD) dementia, pathologically featured as nigrostriatal dopamine (DA) neuronal loss with motor and non-motor manifestations, leads to substantial disability and economic burden. DA therapy targets the DA D3 receptor (D3R) with high affinity and selectivity. The pathological involvement of D3R is evidenced as an effective biomarker for disease progression and DA agnostic interventions, with compensations of increased DA, decreased aggregates of α-synuclein (α-Syn), enhanced secretion of brain-derived neurotrophic factors (BDNF), attenuation of neuroinflammation and oxidative damage, and promoting neurogenesis in the brain. D3R also interacts with D1R to reduce PD-associated motor symptoms and alleviate the side effects of levodopa (L-DOPA) treatment. We recently found that DA D2 receptor (D2R) density decreases in the late-stage PDs, while high D3R or DA D1 receptor (D1R) + D3R densities in the postmortem PD brains correlate with survival advantages. These new essential findings warrant renewed investigations into the understanding of D3R neuron populations and their cross-sectional and longitudinal regulations in PD progression.

Original languageEnglish
Title of host publicationCurrent Topics in Behavioral Neurosciences
PublisherSpringer Science and Business Media Deutschland GmbH
Number of pages19
StatePublished - 2023

Publication series

NameCurrent Topics in Behavioral Neurosciences
ISSN (Print)1866-3370
ISSN (Electronic)1866-3389


  • BDNF
  • Dopamine D3 receptor
  • Neuroinflammation
  • Parkinson disease
  • Progression
  • Survival
  • α-Synuclein


Dive into the research topics of 'Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target'. Together they form a unique fingerprint.

Cite this